According to USAMRIID scientists, animal studies to test the efficacy of these nanoviricides drug candidates against Ebola infection will be undertaken shortly. It is hoped that success against the deadly Ebola virus will lead to further success against other virulent pathogens such as hanta viruses, Marburg virus, Junin virus, Machupo virus, and Rift Valley fever virus.
Eugene Seymour, CEO of NanoViricides, said: “The fact that the same drug candidates that were highly effective against common influenza and rabies in animal studies and bird flu (H5N1) in cell culture studies were also found to be highly effective against the deadly Ebola virus clearly indicates that these nanoviricides are truly broad-spectrum.”